Evaluating the effectiveness of a Diabetes Needs Assessment Tool (DNAT): a randomised controlled trial

Submission date Recruitment status [X] Prospectively registered 29/01/2009 No longer recruiting [X] Protocol [] Statistical analysis plan Registration date Overall study status 30/01/2009 Completed [X] Results [] Individual participant data Last Edited Condition category Nutritional, Metabolic, Endocrine 11/01/2018

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Dean Jenkins

Contact details

Cardiff Medicentre
Heath Park
Cardiff
United Kingdom
CF14 4UJ
+44 (0)2920 757744
DJenkins@bmjgroup.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Evaluating the effectiveness of using a Diabetes Needs Assessment Tool (DNAT) on health professionals' knowledge of diabetes and self-reported changes in clinical practice: a randomised controlled trial

Study objectives

Amended as of 26/03/2009:

Aims:

- 1. To evaluate the effectiveness of using a new online Diabetes Needs Assessment Tool (DNAT) to improve knowledge of how to manage diabetes
- 2. To evaluate the acceptability of this format of learning
- 3. To evaluate self-reported changes in clinical practice as a result of this learning

Hypotheses:

- 1. Four months after being administered the online learning materials, learners in the intervention group will show greater diabetes knowledge and report higher levels of acceptability of the learning materials than learners in the control group
- 2. Five months after being administered the online learning materials, learners in the intervention group will report more changes to their clinical practice than learners in the control group

Initial information at the time of registration:

Aims:

- 1. To evaluate the effectiveness of using a new online Diabetes Needs Assessment Tool (DNAT) to improve knowledge of how to manage diabetes
- 2. To evaluate the acceptability of this format of learning
- 3. To evaluate self-reported changes in clinical practice as a result of this learning

Hypotheses:

- 1. Four months after being administered the online learning materials, learners in the intervention group will show greater knowledge change and report higher levels of acceptability of the learning materials than learners in the control group
- 2. Five months after being administered the online learning materials, learners in the intervention group will report more changes to their clinical practice than learners in the control group

Ethics approval required

Old ethics approval format

Ethics approval(s)

As of 11/02/2009 the REC for Wales has confirmed that the study does not require full ethical review

Study design

Multicentre randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Diabetes

Interventions

Both the control group and the intervention group will be given access to the same online Diabetes Learning Modules during a 4-month learning period. The Diabetes Learning Modules include:

- 1. Current evidence-based guidelines (particularly those of the European Society of Cardiology and the European Association for the Study of Diabetes [ESC-EASD] Guidelines on Diabetes, Prediabetes and Cardiovascular Disease)
- 2. Important clinical areas and common difficulties in practice
- 3. Type 1, Type 2, diabetes in pregnancy and secondary causes of diabetes All content of these learning modules is applicable to European practice and material comes from BMJ Learning, Elsevier Health Sciences and the International Diabetes Federation.

In addition to the Diabetes Learning Modules, the intervention group will be administered the Diabetes Needs Assessment Tool (DNAT). The DNAT is a computerised adaptive test comprised of clinically rich case problems. On completion of the DNAT, a personalised learning report is created for each learner identifying their learning needs alongside individualised recommendations of the most appropriate Diabetes Learning Modules to meet those needs. At any stage this personalised report can be viewed listing the performance of the learner at that point.

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

Amended as of 26/03/2009:

Diabetes knowledge as measured by the Diabetes Knowledge Test at four months.

Initial information at the time of registration:

Change in knowledge scores on the Diabetes Knowledge Test from baseline (randomisation) to 4 months after administration of learning materials.

Secondary outcome measures

- 1. Acceptability of the learning materials measured by an electronic survey 4 months after being administered the learning materials
- 2. Self-reported changes in clinical practice measured by an electronic survey 5 months after being administered the learning materials

Overall study start date

06/02/2009

Completion date

25/09/2009

Eligibility

Key inclusion criteria

Participants must be either English or German speaking practising doctors or nurses (approximately 20 - 65 years, either sex) managing at least one patient with diabetes a week.

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

200

Key exclusion criteria

Doctors and nurses not managing at least one patient with diabetes a week.

Date of first enrolment

06/02/2009

Date of final enrolment

25/09/2009

Locations

Countries of recruitment

Germany

United Kingdom

Wales

Study participating centre

Cardiff Medicentre

Cardiff United Kingdom CF14 4UJ

Sponsor information

Organisation

BMJ Group (UK)

Sponsor details

c/o Mrs Vanessa Edmonds BMA House Tavistock Square London United Kingdom WC1H 9JR +44 (0)20 7383 6567 vedmonds@bmjgroup.com

Sponsor type

Industry

Website

http://group.bmj.com/

ROR

https://ror.org/02caz1f24

Funder(s)

Funder type

Industry

Funder Name

Merck Sharp and Dohme Regional Business Support Center (MSD RBSC) GmbH (Germany) - involved in design of study but no access to data or statistical analyses

Funder Name

BMJ Group (UK) - not involved in statistical analyses

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Protocol article</u>	protocol	30/07/2009		Yes	No
Results article	results	16/06/2011		Yes	No